国产瑞替普酶和尿激酶治疗急性心肌梗死疗效分析

目的 观察国产瑞替普酶和尿激酶治疗ST段抬高型急性心肌梗死的疗效.方法 回顾性分析106例STEMI患者的临床资料.根据溶栓药物不同将患者分为瑞替普酶治疗组53例,尿激酶治疗组53例,比较两组患者的再通率、心功能、出院存活率、住院天数、出血率,以及低血压、休克、恶性心律失常发生率和心脏骤停、心衰发生率的差别.结果 国产瑞替普酶组在再通率、心功能恢复、出院存活率、住院天数、出血率及低血压、休克、恶性心律失常发生率,心脏骤停发生率和心衰发生率方面与尿激酶组比较差异有统计学意义（P＜0.05）.结论 国产瑞替普酶较尿激酶对急性ST段抬高型心肌梗死有良好的疗效.

Effects of Retaplase and Urokinase in patients with acute myocardial infarction

Objective To investigate the effects of Retaplase and Urokinase in patients with acute ST elevating myocardial infarction（STEMI）. Methods 106 STEMI patients were divided into 2 groups by using Reteplase or Urokinase. 53 patients used Retaplase and 53 patients used Urokinase. The reeanalization rate, ejecting fraction, survival to hospital discharge, the hospital day, haemorrhagic rate, hypotension, shock, malignant arrhythmia, sudden death and the heart ffailure rate were observed. Results The recanalization rate, ejecting fraction, survival to hospital discharge, the duration of hospitalization, haemorrhagic rate ,hy- potension shock, malignant arrhythmia, sudden death,the heart failure rate were statistically significant dif- ferences between Retaplase and Urokinase. Conclusion Retaplase have good effects in STEMI.